Johnson and Johnson Pharmaceutical Research and Development, LLC (NJ)

41 articles with Johnson and Johnson Pharmaceutical Research and Development, LLC (NJ)

• Johnson & Johnson to Participate in Citi's 2022 Virtual Healthcare Conference

  1/27/2022

  Johnson & Johnson (NYSE: JNJ) will participate in Citi's 2022 Virtual Healthcare Conference on Wednesday, February 23rd, Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices will represent the Company in a session scheduled at 11:00 a.m. (Eastern Time).

• Real World Evidence Shows Johnson & Johnson COVID-19 Vaccine Demonstrates Durable Protection Against Breakthrough Infection, Hospitalization, and Intensive Care Unit Admission in the United States

  1/6/2022

  Johnson & Johnson (NYSE: JNJ) (the Company) today announced new results from the largest study to date on the durability of COVID-19 vaccines in the United States (U.S.), showing that a single shot of the Johnson & Johnson COVID-19 vaccine resulted in long-lasting protection for up to six months against COVID-19 breakthrough infections, hospitalizations, and intensive care unit (ICU) admissions.

• Johnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19 Vaccine

  12/15/2021

  Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion for use of the Company's COVID-19 vaccine as a booster for adults aged 18 and older at least two months after primary vaccination with a single-shot of the Johnson & Johnson COVID-19 vaccine.

• Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee

  10/15/2021

   Johnson & Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted 19-0 to recommend Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older.

• 

  Evidence Building for a Mix and Match Approach to COVID-19 Vaccines

  7/12/2021

  Morgan had determined that adding one dose of the Moderna or Pfizer-BioNTech mRNA vaccine to one of Oxford-AstraZeneca’s viral vector technology would equal stronger immunity. 

• Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine

  8/5/2020

  Johnson & Johnson (NYSE: JNJ) (the Company) today announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing an

• FDA Approves Johnson & Johnson Pharmaceutical Research & Development, LLC (CA)'s (JOBS) INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

  8/3/2009

• Bayer AG and Johnson and Johnson Pharmaceutical Research and Development, LLC (NJ) Release: Phase II Trial of Experimental Anti-Coagulant Reports Safety and Outcomes Data

  11/11/2008

• Tekmira Pharmaceuticals Corporation Announces Presentation of Data Using SNALP RNAi Delivery Technology

  10/22/2008

• Johnson and Johnson Pharmaceutical Research and Development, LLC (NJ) Submits New Drug Application to FDA for Rivaroxaban

  7/30/2008

• Doribax Shows Shorter Hospital Stays In Ventilator-Associated Pneumonia Patients, Johnson and Johnson Pharmaceutical Research and Development, LLC (NJ) Study

  5/16/2008

• Sareum Ltd. Extension of Collaboration with Johnson and Johnson Pharmaceutical R&D (NJ)

  3/31/2008

• Johnson and Johnson Pharmaceutical R&D (NJ), Basilea Pharmaceutica Key Drug Fails to Get FDA Approval; Stock Dives

  3/18/2008

• Johnson and Johnson Pharmaceutical Research and Development, LLC (NJ) Says FDA Delays Antibiotic Review by 3 Months

  3/7/2008

• Johnson and Johnson Pharmaceutical R&D (NJ) New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets

  1/24/2008

• Johnson and Johnson Pharmaceutical R&D (NJ) Release: Three Phase III Trials Show Rivaroxaban Outperformed Enoxaparin in Preventing Venous Thromboembolism After Major Orthopedic Surgery

  12/10/2007

• Johnson and Johnson Pharmaceutical R&D (NJ) New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections

  10/8/2007

• Janssen, L.P. and Johnson and Johnson Pharmaceutical R&D (NJ) Release: FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania

  8/22/2007

• FDA Issues Approvable Letter for Johnson and Johnson Pharmaceutical R&D (NJ)'s (Jobs) RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania

  6/21/2007

• Johnson and Johnson Pharmaceutical R&D (NJ) Release: New Drug Application Submitted for Investigational Antibiotic Doripenem

  6/6/2007